MY ACCOUNT | NEWSLETTER |

FDA approves first generic maropitant citrate tablets for use in dogs to prevent vomiting


In late March 2023, the U.S. Food and Drug Administration approved Maropitant Citrate tablets for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. This news was recently highlighted by Roxanne Hawn, a freelance reporter, on the blog, "Champion of My Heart." 

In the blog post, Hawn wrote about her dog's experience with Cerenia and what this approval means for pet parents. 

According to a FDA news release, Maropitant Citrate is an antiemetic drug that contains the same active ingredient (maropitant citrate) in the same concentration and dosage form as the approved brand name drug product, Cerenia tablets, which was first approved on January 29, 2007.  In addition, the FDA determined that Maropitant Citrate tablets contain no inactive ingredients that may significantly affect the bioavailability of the active ingredient.

Maropitant Citrate is only available by prescription from a licensed veterinarian because professional veterinary expertise is needed to determine whether Maropitant Citrate is an appropriate treatment.

The product labeling warns that people handling, administering, or exposed to Maropitant Citrate may have allergic skin reactions if they get the product on their skin. People administering the product should wash their hands with soap and water after administering the drug. Maropitant Citrate may also cause eye irritation if the product gets in the eye. In the case of accidental eye exposure, people should flush their eyes with water for 15 minutes and seek medical attention.

Maropitant Citrate is supplied in 16, 24, 60 or 160 mg of maropitant as maropitant citrate per tablet. Each tablet strength is scored and packaged in blister packs containing four tablets per perforated sheet.

Maropitant Citrate is sponsored by ZyVet Animal Health Inc., based in Pennington, New Jersey.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Experimental Vaccine Protection Against Feline Immunodeficiency Virus

Like0
Dislike0

In vitro force mapping of normal canine humeroradial and humeroulnar joints

Like0
Dislike0

Prevalence of antibodies to Haemophilus pleuropneumoniae in Iowa swine

Like0
Dislike0

Breakthrough takes big step toward safe, reversible male contraception

Like0
Dislike0

IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top